Thursday, July 15, 2010

States Ban Marijuana Replacement Therapy (K2), Nicotine Replacement "Therapy" Should Be Included

There has been recent media attention and fear mongering regarding the smoking of herbs laced with synthetic marijuana. Supposedly, people are showing up in emergency rooms vomiting, hallucinating, and poisoned after using synthetic marijuana which is often marketed as incense. There is even one reported suicide alledgedly linked to the synthetic marijuana, also called K2. One suicide, a few possible vomiting patients.

The problem is that synthetic marijuana is being made by too many small businesses and not a large pharmaceutical monopoly. If synthetic marijuana were being made and marketed as "therapy" for a malady and provided to patients with state subsidies, the way Nicotine Replacement "Therapy" (NRT) and Varenicline are it wouldn't matter how many people vomited, hallucinated, committed suicide or died from high blood pressure. Thousands could die and it would be lauded as a great thing, a final solution to health problems, a cure.

There are no media investigations into the thousands, perhaps millions, of lives ruined by Nicotine Replacement "Therapy," or Varenicline. There are no statistics being kept (that I know of) on how many heart attacks have occurred as a result of the transdermal nicotine patch, or cancers caused by the gums and candies.

One person kills them self on synthetic marijuana, while hundreds have killed themselves or committed violence against others on Varenicline. A few people have temporarily hallucinated on synthetic marijuana, while thousands have been made into psychiatric patients after being legally prescribed Varenicline as a quit smoking aid -- with our tax dollars.

So far, it appears that unregulated street chemists offer safer synthetics than the State Pharmaceutical chemists and dealers, and this is bothersome to these corporations.

See "Synthetic Marijuana Spurs State Bans," Malcolm Gay, New York Times, 1o July 2010
http://www.nytimes.com/2010/07/11/us/11k2.html?_r=1

No comments: